Soluble interleukin-7 receptor (sIL7R) modulation therapy for treating cancer
Patent Information
- Application Number
- JP2023527326
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-10-29
- Filing Date
- 2021-10-29
- Publication Date
- 2024-11-07
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
【0014】 別の態様では、該オリゴヌクレオチド内の少なくとも1個またはそれより多くのヌクレオチドが、ヌクレオチド塩基に対する天然に存在しない修飾を含む。別の態様では、該オリゴヌクレオチドが、表1のSM-ASOの任意のSEQ ID(SM-ASOの配列番号:1~13)またはその一部分の単独または組合せのいずれか、あるいはIL7R RNA内の標的の完全配列において少なくとも70、75、80、84、85、88、92、93、94、95または96%の相補性およびまたは同一性を有する配列から選択される。別の態様では、該オリゴヌクレオチドが、表2の任意の標的SEQ ID(標的配列番号:1~13)を全体または部分的のいずれかで標的化する。別の態様では、該組成物が薬学的に許容され得る賦形剤、塩または担体をさらに含む。別の態様では、該疾患または病状が、以下のもの:多発性硬化症、I型糖尿病、関節リウマチ、全身性エリテマトーデス、アトピー性皮膚炎、強直性脊椎炎、原発性胆汁性肝硬変または炎症性腸症候群、例えば潰瘍性大腸炎、クローン病または疾患もしくは病状のない正常被験体と比較した場合、sIL7Rが高値である任意の他の病状のうちの少なくとも1つから選択される自己免疫障害である。別の態様では、該疾患または病状が炎症性の疾患または病状である。別の態様では、該オリゴヌクレオチドが、例えば、sIL7R RNAの安定性を低下させる(例えば、分解を増大させる)ASO、siRNA、shRNAおよび/またはsIL7R RNAの翻訳を低減させるASOを用いてIL7Rのエクソン5-エクソン7の境界を標的化することにより、エクソン6が欠損しているIL7R mRNAの分解を促進させる。別の態様では、該方法が、SM-ASOと自己免疫疾患の処置に有効な1種類またはそれより多くの活性薬剤、例えば限定されないがミトキサントロン、インターフェロンベータ-1a、PEG-インターフェロンベータ-1a、アザチオプリン、フィンゴリモド、ナタリズマブ、メチルプレドニゾロンまたはオクレリズマブとの併用療法をさらに含む。別の態様では、該方法が、患者から細胞を得、該細胞を、エクソン6のスプライシングに影響を及ぼすインターロイキン-7受容体(IL7R)プレmRNAの配列に特異的に結合する該オリゴヌクレオチドを一過的または永久的に発現するように修飾する工程をさらに含む。別の態様では、該方法が、遺伝子治療における使用のための、エクソン6のスプライシングに影響を及ぼすインターロイキン-7受容体(IL7R)プレmRNAの配列に特異的に結合する該オリゴヌクレオチドを発現するベクターを作成すること、および該患者を、該ベクターを用いて処置することをさらに含む。
Smart Images

Figure 00000000_0000_ABST
Abstract
Claims
1. A composition comprising an oligonucleotide that binds to a sequence within the pre-mRNA of interleukin-7 receptor (IL7R) that affects splicing of exon 6, wherein the oligonucleotide increases the exclusion of exon 6 in the IL7R pre-mRNA and increases expression of the soluble isoform of IL7R (sIL7R).
2. The composition of claim 1, wherein the oligonucleotide is an antisense oligonucleotide (ASO) or a splice modulation antisense oligonucleotide (SM-ASO).
3. 2. The composition of claim 1, wherein the oligonucleotide is selected from a sequence having at least 70, 75, 80, 84, 85, 88, 92, 93, 94, 95 or 96% complementarity to SEQ ID NO:27 or SEQ ID NO:30, or SEQ ID NO:64 or SEQ ID NO:
67.
4. The composition of claim 1 adapted for administration to treat cancer.
5. The composition of claim 1 further comprising a pharma- ceutically acceptable excipient, salt or carrier.
6. 10. The composition of claim 1, further comprising one or more active agents for the treatment of cancer.
7. The composition described in claim 1, wherein one or more of the oligonucleotide's (1) ribose or other sugar unit, (2) base, or (3) backbone are modified.
8. 2. The composition of claim 1, which is modified to have nucleotides having phosphate group modifications including one or more phosphorothioate, phosphorodithioate, phosphodiester, methylphosphonate, phosphoramidate, methylphosphonate, phosphotriester, phosphoralidate, morpholino, amidate carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, or alkylsilyl substitutions, and combinations of two or more of any of the foregoing.
9. Sugar modifications, such as 2'-O-methyl (2'-O-methyl nucleotides) and 2'-O-methyloxyethoxy (2'-O-MOE), 2'-O-alkyl modified sugar moieties or bicyclic sugar moieties and nucleotide mimetics, such as, but not limited to, peptide nucleic acids (PNAs), morpholino nucleic acids, cyclohexenyl nucleic acids, anhydrohexitol nucleic acids, glycol nucleic acids, threose nucleic acids and locked nucleic acids (LNAs), as well as partially or fully modified backbones, such as fully modified sugar phosphate backbones, locked nucleic acid backbones, peptidic backbones, phosphotriester backbones, phosphoramidate backbones, siloxane backbones. , a carboxymethyl ester backbone, an acetamidate backbone, a carbamate backbone, a thioether backbone, a bridged methylene phosphonate backbone, a phosphorothioate backbone, a methyl phosphonate backbone, an alkyl phosphonate backbone, a phosphate ester backbone, an alkyl phosphonothioate backbone, a phosphorodithioate backbone, a carbonate backbone, a phosphate triester backbone, a carboxymethyl ester backbone, a methyl phosphorothioate backbone, a phosphorodithioate backbone, a backbone having a p-ethoxy bond, and combinations of two or more of any of the foregoing.
10. The composition of claim 1, wherein the oligonucleotide is modified with a peptide, a cell membrane-permeable peptide, an antibody, a nanobody, a camelid portion, an antibody variable region, a small molecule, and / or a ligand that enhances the stability of the oligonucleotide, distribution or delivery of the oligonucleotide to a specific tissue.
11. The composition described in claim 6, wherein the one or more active agents for the treatment of cancer are selected from immune checkpoint inhibitors, therapeutic antibodies, chemotherapeutic agents and therapeutic radiation.
12. The composition described in claim 10, wherein the ligand is a protein, lipid or carbohydrate that promotes or can promote the stability, distribution or delivery of the oligonucleotide to a specific tissue.
13. The composition of claim 1, wherein the oligonucleotide has a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to a nucleotide selected from SEQ ID NOs:27-63.
14. The composition of claim 1, wherein the oligonucleotide binds completely or partially to a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to a nucleotide selected from SEQ ID NOs:64-100.
15. A composition for use in a method for treating cancer, comprising the oligonucleotide of claim 1.
16. The cancer is colorectal cancer, liver cancer, cholangiocarcinoma, hepatocellular carcinoma, melanoma, lung cancer, adenocarcinoma, squamous cell carcinoma, large cell (undifferentiated) carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer, kidney cancer, renal cell carcinoma, squamous cell carcinoma of the esophagus, head and neck cancer, urothelial carcinoma, cervical cancer, squamous cell carcinoma of the skin, endometrial cancer, gastric cancer, gastroesophageal junction cancer, esophageal cancer, microsatellite instability-high (MSI-H) or mismatch repair deficient (dM 16. The composition of claim 15, wherein the cancer is one or more of breast cancer, solid tumors, triple negative breast cancer, triple positive breast cancer, brain cancer, astrocytoma, ependymoma, glioma, meningioma, medulloblastoma, neuroblastoma, bladder cancer, childhood cancer, multiple myeloma, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma, skin cancer, Merkel cell carcinoma (MCC), Kaposi's sarcoma (KS), gastric cancer, and uterine cancer.
17. The composition of claim 15, wherein the composition is administered together with a second therapeutic agent, the second therapeutic agent being selected from an immune checkpoint inhibitor, a therapeutic antibody, a chemotherapeutic agent or therapeutic radiation.
18. The composition described in claim 15, which promotes the activity or efficacy of immunotherapy.
19. The composition described in claim 18, wherein the immunotherapy includes administration of an immune checkpoint inhibitor.
20. A composition for promoting responsiveness to cancer treatment, comprising the oligonucleotide described in claim 1.
21. The composition described in claim 20, wherein the treatment of the cancer comprises administration of an immune checkpoint inhibitor.
22. The composition of claim 15, which is administered topically, enterally, parenterally, intravaginally, nasally, ophthalmically, buccal, subcutaneously, intravenously, intramuscularly, intraperitoneally, intranasally, sublingually, intrathecally, rectally, orally or by inhalation.
